Gastrointestinal dysfunction in Parkinson's disease.
Constipation
Dysmotility
Gastrointestinal dysfunction
Gastroparesis
Parkinson’s disease
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
29
11
2019
accepted:
20
01
2020
revised:
17
01
2020
pubmed:
29
1
2020
medline:
9
2
2021
entrez:
29
1
2020
Statut:
ppublish
Résumé
Gastrointestinal (GI) dysfunction is prevalent in Parkinson's disease (PD). Symptoms are evident throughout the disease course, affect the length of the GI tract and impact on patient quality of life and management. We clarify real-life differences in the frequency and severity of GI symptoms in a cohort of PD and healthy control (HC) subjects. 103 PD patients were compared to 81 HC subjects. Outcome measures collected from validated questionnaires included constipation severity, upper and lower GI symptoms and physical activity. PD patients were three-times more likely to experience constipation than HC subjects, (78.6% vs 28.4%), exhibited a fourfold increase in constipation severity and formed harder stools. PD patients also reported increased symptoms of indigestion, nausea, excessive fullness and bloating, compared to the HCs. A higher mean Leeds Dyspepsia Questionnaire score for PD patients (8.3 (standard deviation (SD) 7.7) vs 4.6 (SD 6.1), p = 0.001)) indicated increased symptom severity. Chronic pain was more frequently reported and correlated with constipation and upper GI dysfunction, being more prevalent and severe in women. Physical activity was notably decreased in the PD cohort (1823.6 (± 1693.6) vs 2942.4 (± 2620.9) metabolic equivalent-minutes/week, p = 0.001) and correlated with constipation severity. PD therapies were associated with increased fullness and bloating and harder stools. PD patients report more prevalent and severe GI dysfunction, although our cohort comprised of many later-stage participants. Earlier recognition of GI dysfunction in PD provides the opportunity to direct treatment for chronic pain and constipation, promote physical activity and rationalise PD therapies for optimal patient care.
Sections du résumé
BACKGROUND
BACKGROUND
Gastrointestinal (GI) dysfunction is prevalent in Parkinson's disease (PD). Symptoms are evident throughout the disease course, affect the length of the GI tract and impact on patient quality of life and management. We clarify real-life differences in the frequency and severity of GI symptoms in a cohort of PD and healthy control (HC) subjects.
METHODS
METHODS
103 PD patients were compared to 81 HC subjects. Outcome measures collected from validated questionnaires included constipation severity, upper and lower GI symptoms and physical activity.
RESULTS
RESULTS
PD patients were three-times more likely to experience constipation than HC subjects, (78.6% vs 28.4%), exhibited a fourfold increase in constipation severity and formed harder stools. PD patients also reported increased symptoms of indigestion, nausea, excessive fullness and bloating, compared to the HCs. A higher mean Leeds Dyspepsia Questionnaire score for PD patients (8.3 (standard deviation (SD) 7.7) vs 4.6 (SD 6.1), p = 0.001)) indicated increased symptom severity. Chronic pain was more frequently reported and correlated with constipation and upper GI dysfunction, being more prevalent and severe in women. Physical activity was notably decreased in the PD cohort (1823.6 (± 1693.6) vs 2942.4 (± 2620.9) metabolic equivalent-minutes/week, p = 0.001) and correlated with constipation severity. PD therapies were associated with increased fullness and bloating and harder stools.
CONCLUSIONS
CONCLUSIONS
PD patients report more prevalent and severe GI dysfunction, although our cohort comprised of many later-stage participants. Earlier recognition of GI dysfunction in PD provides the opportunity to direct treatment for chronic pain and constipation, promote physical activity and rationalise PD therapies for optimal patient care.
Identifiants
pubmed: 31989280
doi: 10.1007/s00415-020-09723-5
pii: 10.1007/s00415-020-09723-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1377-1388Références
Lubomski M, Rushworth RL, Tisch S (2015) Hospitalisation and comorbidities in Parkinson's disease: a large Australian retrospective study. J Neurol Neurosurg Psychiatry 86(3):324–330
pubmed: 24876185
doi: 10.1136/jnnp-2014-307822
Makaroff L, Gunn A, Gervasoni C, Richy F (2011) Gastrointestinal disorders in Parkinson's disease: prevalence and health outcomes in a US claims database. J Parkinson's Dis 1(1):65–74
doi: 10.3233/JPD-2011-001
Pfeiffer RF (2003) Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2(2):107–116
pubmed: 12849267
doi: 10.1016/S1474-4422(03)00307-7
Yu QJ, Yu SY, Zuo LJ, Lian TH, Hu Y, Wang RD et al (2018) Parkinson disease with constipation: clinical features and relevant factors. Sci Rep 8(1):567
pubmed: 29330419
pmcid: 5766597
doi: 10.1038/s41598-017-16790-8
Poirier AA, Aube B, Cote M, Morin N, Di Paolo T, Soulet D (2016) Gastrointestinal dysfunctions in Parkinson's disease: symptoms and treatments. Parkinsons Dis 2016:6762528
pubmed: 28050310
pmcid: 5168460
Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD et al (2001) Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57(3):456–462
pubmed: 11502913
doi: 10.1212/WNL.57.3.456
Savica R, Carlin JM, Grossardt BR, Bower JH, Ahlskog JE, Maraganore DM et al (2009) Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology. 73(21):1752–1758
pubmed: 19933976
pmcid: 2788809
doi: 10.1212/WNL.0b013e3181c34af5
Klingelhoefer L, Reichmann H (2017) The gut and nonmotor symptoms in Parkinson's disease. Int Rev Neurobiol. 134:787–809
pubmed: 28805583
doi: 10.1016/bs.irn.2017.05.027
Cersosimo MG, Benarroch EE (2012) Pathological correlates of gastrointestinal dysfunction in Parkinson's disease. Neurobiol Dis. 46(3):559–564
pubmed: 22048068
doi: 10.1016/j.nbd.2011.10.014
Lebouvier T, Neunlist M, Bruley des Varannes S, Coron E, Drouard A, N'Guyen JM, et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One 2010;5(9):e12728.
pubmed: 20856865
pmcid: 2939055
doi: 10.1371/journal.pone.0012728
Park A, Stacy M (2009) Non-motor symptoms in Parkinson's disease. J Neurol. 256(Suppl 3):293–298
pubmed: 19711119
doi: 10.1007/s00415-009-5240-1
Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF (2015) Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 14(6):625–639
pubmed: 25987282
doi: 10.1016/S1474-4422(15)00007-1
Guneysel O, Onultan O, Onur O (2008) Parkinson's disease and the frequent reasons for emergency admission. Neuropsychiatr Dis Treat. 4(4):711–714
pubmed: 19043514
pmcid: 2536537
doi: 10.2147/NDT.S3007
Knudsen K, Krogh K, Ostergaard K, Borghammer P (2017) Constipation in parkinson's disease: subjective symptoms, objective markers, and new perspectives. Mov Disord 32(1):94–105
pubmed: 27873359
doi: 10.1002/mds.26866
Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF (1994) Characterization of swallowing and defecation in Parkinson's disease. Am J Gastroenterol. 89(1):15–25
pubmed: 8273792
Ashraf W, Pfeiffer RF, Quigley EM (1994) Anorectal manometry in the assessment of anorectal function in Parkinson's disease: a comparison with chronic idiopathic constipation. Mov Disord 9(6):655–663
pubmed: 7845407
doi: 10.1002/mds.870090612
Camacho M, Evans J, Breen D, Cummins G, Wijeyekoon R, Scott K et al (2018) Early gastrointestinal dysfunction is predictive of faster progression in Parkinson's disease. Mov Disord 33(Supplement 2):S729
Djaldetti R, Baron J, Ziv I, Melamed E (1996) Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology. 46(4):1051–1054
pubmed: 8780089
doi: 10.1212/WNL.46.4.1051
Pfeiffer RF (2018) Gastrointestinal dysfunction in Parkinson's disease. Curr Treat Opt Neurol 20(12) (no pagination)(54)
Lubomski M, Tan AH, Lim SY, Holmes AJ, Davis RL, Sue CM (2019) Parkinson's disease and the gastrointestinal microbiome. J Neurol. https://doi.org/10.1007/s00415-019-09320-1
doi: 10.1007/s00415-019-09320-1
pubmed: 31041582
Lubomski M, Davis RL, Sue CM (2019) The gut microbiota: a novel therapeutic target in Parkinson's disease? Parkinsonism Relat Disord
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184
pubmed: 1564476
pmcid: 1014720
doi: 10.1136/jnnp.55.3.181
Lewis SJ, Heaton KW (1997) Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 32(9):920–924
pubmed: 9299672
doi: 10.3109/00365529709011203
Moayyedi P, Duffett S, Braunholtz D, Mason S, Richards ID, Dowell AC et al (1998) The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsia. Aliment Pharmacol Ther 12(12):1257–1262
pubmed: 9882035
doi: 10.1046/j.1365-2036.1998.00404.x
Sood R, Ford AC (2016) Diagnosis: Rome IV criteria for FGIDs—an improvement or more of the same? Nat Rev Gastroenterol Hepatol 13(9):501–502
pubmed: 27407043
doi: 10.1038/nrgastro.2016.110
Agachan F, Chen T, Pfeifer J, Reissman P, Wexner SD (1996) A constipation scoring system to simplify evaluation and management of constipated patients. Dis Colon Rectum 39(6):681–685
pubmed: 8646957
doi: 10.1007/BF02056950
Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 22(13):1901–1911
pubmed: 17674410
doi: 10.1002/mds.21596
Hagstromer M, Oja P, Sjostrom M (2006) The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public Health Nutr 9(6):755–762
pubmed: 16925881
doi: 10.1079/PHN2005898
Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129–2170
pubmed: 19025984
doi: 10.1002/mds.22340
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 25(15):2649–2653
pubmed: 21069833
doi: 10.1002/mds.23429
McCormack HM, Horne DJ, Sheather S (1988) Clinical applications of visual analogue scales: a critical review. Psychol Med. 18(4):1007–1019
pubmed: 3078045
doi: 10.1017/S0033291700009934
Saad RJ, Rao SS, Koch KL, Kuo B, Parkman HP, McCallum RW et al (2010) Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. Am J Gastroenterol. 105(2):403–411
pubmed: 19888202
doi: 10.1038/ajg.2009.612
Knudsen K, Szwebs M, Hansen AK, Borghammer P (2018) Gastric emptying in Parkinson's disease—a mini-review. Parkinsonism Relat Disord 55:18–25
pubmed: 29891432
doi: 10.1016/j.parkreldis.2018.06.003
Mylius V, Ciampi de Andrade D, Cury RG, Teepker M, Ehrt U, Eggert KM et al (2015) Pain in Parkinson's disease: current concepts and a new diagnostic algorithm. Mov Disord Clin Pract 2(4):357–364
pubmed: 30363602
pmcid: 6178768
doi: 10.1002/mdc3.12217
Ford B (2010) Pain in Parkinson's disease. Mov Disord. 25(Suppl 1):S98–103
pubmed: 20187254
doi: 10.1002/mds.22716
Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD (2002) Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol. 155(8):732–738
pubmed: 11943691
doi: 10.1093/aje/155.8.732
Budrewicz S, Zmarzly A, Raczka D, Szczepanska A, Koziorowska-Gawron E, Slotwinski K et al (2019) Clinical and nutritional correlations in Parkinson's disease: preliminary report. Adv Clin Exp Med. 28(2):193–198
pubmed: 29963785
doi: 10.17219/acem/76375
Recasens A, Dehay B (2014) Alpha-synuclein spreading in Parkinson's disease. Front Neuroanat. 8:159
pubmed: 25565982
pmcid: 4270285
doi: 10.3389/fnana.2014.00159
Lee HJ, Jung KW, Chung SJ, Hong SM, Kim J, Lee JH et al (2018) Relation of enteric alpha-Synuclein to gastrointestinal dysfunction in patients with Parkinson's disease and in neurologically intact subjects. J Neurogastroenterol Motil. 24(3):469–478
pubmed: 29969861
pmcid: 6034677
doi: 10.5056/jnm17141
Lubomski M, Louise Rushworth R, Lee W, Bertram KL, Williams DR (2014) Sex differences in Parkinson's disease. J Clin Neurosci. 21(9):1503–1506
pubmed: 24767694
doi: 10.1016/j.jocn.2013.12.016
Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH et al (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 13(2):141–149
pubmed: 24361112
doi: 10.1016/S1474-4422(13)70293-X
Higgins PD, Johanson JF (2004) Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 99(4):750–759
pubmed: 15089911
doi: 10.1111/j.1572-0241.2004.04114.x
Fragakis A, Zhou J, Mannan H, Ho V (2018) Association between drug usage and constipation in the elderly population of greater Western Sydney Australia. Int J Environ Res Public Health 15(2):226
pmcid: 5858295
doi: 10.3390/ijerph15020226
Yang J, Wang HP, Zhou L, Xu CF (2012) Effect of dietary fiber on constipation: a meta analysis. World J Gastroenterol 18(48):7378–7383
pubmed: 23326148
pmcid: 3544045
doi: 10.3748/wjg.v18.i48.7378
Lubomski M, Rushworth RL, Lee W, Bertram K, Williams DR (2013) A cross-sectional study of clinical management, and provision of health services and their utilisation, by patients with Parkinson's disease in urban and regional Victoria. J Clin Neurosci. 20(1):102–106
pubmed: 23098389
doi: 10.1016/j.jocn.2012.05.015